Recovering scientist turned early stage VC A biotech optimist fighting gravity

Hiring:  Using Your Team To Build A Team
June 16, 2017

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much has been said about who and when to hire in this blog (here and here for example), but

Leave a comment

Getting Personal at ASCO 2017: Precision Therapies, IO, and Autologous Cell Therapy
June 13, 2017

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. The 2017 American Society of Clinical Oncology (“ASCO”) meeting concluded last week, providing patients, physicians, and industry stakeholders with

1 Comment

The Road to Lexington: RaNA’s Midnight Ride Ignites the mRNA Revolution
June 2, 2017

This blog was written by Brian Fenton and Paul Burgess, CBO and GC of RaNA Therapeutics, respectively, as part of the From The Trenches feature of LifeSciVC.  On April 18, 1775, Paul Revere was summoned by Dr. Joseph Warren of

Leave a comment

Team Atlas Expands Its Roster With Kevin Bitterman
June 1, 2017

We’re excited to announce Kevin Bitterman has joined Atlas Venture as a partner! Kevin is well known in the Boston biotech ecosystem, having spent the last dozen-plus years on the life science team at Polaris Partners. He brings a great

Leave a comment

Getting Struck Twice: Acquisitions & Spinouts In Biotech
May 25, 2017

Lightning can definitely strike the same place twice, or so it seems in biotech. The latest example is True North Therapeutics’ recent acquisition by Bioverativ for its program addressing cold agglutinin disease, a type of rare autoimmune hemolytic anemia: it

1 Comment

Human Antibody Discovery: Of Mice And Phage
May 11, 2017

The FDA recently approved Imfinzi (durvalumab) for the treatment of bladder cancer, making it the fifth new monoclonal antibody approved this year. More than twenty antibodies have been approved by the FDA since 2015. While not quite the magic bullet envisioned

Leave a comment

Doing Good To Feel Better: The Expanding Role Of Philanthropy In Drug Development
May 9, 2017

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. As a child, I once played the fiddler in ‘Fiddler on the Roof’. I was a horrible violinist with

Leave a comment

Building A Biotech: Magenta Starts Chapter 2 With A Triple Play
May 2, 2017

This blog was written by Jason Gardner, CEO of Magenta Therapeutics and former EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. We are excited to open the first page of Chapter 2 at Magenta

Leave a comment

Four Decades Of Hacking Biotech And Yet Biology Still Consumes Everything
April 26, 2017

Neural networks, cloud computing, deep learning, and in silico wizardry are on the cusp of disintermediating pharmaceutical drug discovery, cutting billions of billions off the industry’s cost of new drugs and reducing the time to get new medicines approved to

3 Comments

Caveat Subscriptor When Academia Touts A Breakthrough
March 31, 2017

This blog was written by Nessan Bermingham, CEO of Intellia Therapeutics, as part of the From The Trenches feature of LifeSciVC   Academic discoveries are oxygen for entrepreneurs. But, caveat subscriptor – be careful what you sign. Even high profile

1 Comment

The Inescapable Gravity Of Biotech’s Key Clusters: The Great Consolidation Of Talent, Capital, & Returns
March 21, 2017

Two key geographic clusters dominate the biotech landscape today. These two areas, Boston and San Francisco, combine a unique blend of biomedical science, venture capital, entrepreneurial talent, risk-taking culture, and geographic density. Other regions have some or all of these

8 Comments

The Hunt For Novel Treatments Against Deadly Bacteria:  Spero Therapeutics And Its Potentiators
March 16, 2017

This guest blog was written by Troy Lister, Head of Chemistry, and Cristina Larkin, Chief Commercial Officer, of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. A national security threat equivalent to terrorism?  This is how

1 Comment